Latest Boehringer Ingelheim Stories
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
Boehringer Ingelheim launches comprehensive support resources for people with idiopathic pulmonary fibrosis RIDGEFIELD, Conn., Oct.
BONN, Germany, October 14, 2014 /PRNewswire/ -- Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer
RIDGEFIELD, Conn., Oct.
Case Funding Company says recent $650MM settlement of approximately 4K filed cases in both state and federal courts over blood thinner, amounts to an average Pradaxa settlement amount or settlement
As Pradaxa Lawsuit Claims Continue Boehringer Ingelheim Conducts Clinical Trials On Idarucizumab, A Potential Reversal Agent To Pradaxa Columbus, OH (PRWEB)
New Executive Brings Experience from Merck, Boehringer Ingelheim, and Proctor & Gamble PLYMOUTH MEETING, Pa., Sept. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S.
Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.
- The word or words serving to define another word or expression, as in a dictionary entry.